arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

Beam Therapeutics Inc.

BEAM
$25.80 ▼ -2.00 (-7.21%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
32 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
32
Health
Poor
Bearish
auto_awesome

Analytical Summary

Beam Therapeutics Inc. faces fundamental challenges with weakness in Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.7B
Dividend Yield —
Revenue Growth -96.8% ↘
Op. Margin None
ROIC -10.6% ↘
FCF / Share $-1.07 ↘
Trailing P/E —
Price / Book 2.8x
FCF Yield —
Debt / Equity 0.11
info Valuation on last close. End-of-day price, Nov 5, 2026.

32-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$307.00K
↓ -96.8% —
Net Income Profit after all expenses
$-94.32M
↑ +12.9% —
Operating Margin Operating profit as % of sales
-337.8%
↓ -2109.7% 0th
FCF / Share Free cash flow per share
$-1.07
↓ -26.8% —
Long-Term Debt Long-term obligations
$100.36M
— +0.1% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↓
2
Returns ↑
37
Cash Quality ↑
95

bar_chart Data from SEC EDGAR XBRL filings

Synced 6 days ago 8 years · 32 quarters